Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Huadong Pharma Forms $662 Million Collaboration for Anti-Inflammatory Drugs

publication date: Feb 24, 2022

Zhongmei Huadong Pharma announced a $662 million agreement to develop two Kiniksa Pharma ) anti-inflammatory drug candidates in southeast Asia (ex-Japan). Kiniksa, a Boston area company, develops molecules that modulate immunological pathways. Huadong will have rights to Kiniksa’s Arcalyst®, a US approved treatment for recurrent pericarditis, and mavrilimumab, a clinical-stage therapy for rheumatoid arthritis. Huadong will pay $22 million upfront and be responsible for up to $640 million in milestones, plus royalties. Zhongmei Huadong is a division of Huadong Medicine. More details....

Stock Symbols: (NSDQ: KNSA (SHZ: 0963)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.